The agency found that an exhibit panel at a conference made false claims about the drug’s benefits over generic dexamethasone without providing adequate risk information, according to an FDA letter issued to the drugmaker.
According to the letter, the promotional materials suggested Hemady led to better patient adherence compared to generic dexamethasone. However, the study cited to support the claim contained flaws, including inconsistent patient selection criteria, lack of control for key variables and an unbalanced sample size.
The FDA has demanded that Dexcel discontinue these practices and respond within 15 working days with a plan to address the violations, warning that failure to do so would result in further regulatory action.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
